#SHPH hashtag - Bluesky

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a public offering to issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares for aggregate gross proceeds of approximately $3.5 million.The offering is expected to close on or about March 9, 2026, with E.F. Hutton & Co. as exclusive placement agent. The company intends to use up to $1.5 million for marketing and the remainder for working capital and general corporate purposes. The securities are being offered under an effective Form S-1 (File No. 333-293363) registration statement.

3 weeks ago

#SHPH Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Stock Master

@stockmaster70.bsky.social

2 months ago

📢 Stocks Trending NOW: #NFLX #MMM #META #NVDA #IBRX #IVF #SHPH #APP #TWG #CRML

0 0 0 0

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever Shuttle Pharmaceuticals (NASDAQ: SHPH) on January 13, 2026 highlighted Utah's new pilot allowing AI to authorize prescription refills and explained why that regulatory milestone matters for its Molecule.ai drug‑discovery platform. The release links Utah's AI refill program to time and cost savings in healthcare and argues Molecule.ai can similarly cut drug discovery bottlenecks by reducing time to identify candidates, lowering failed‑experiment costs, and automating repetitive screening.The company says Molecule.ai uses agentic AI with uncertainty quantification, human‑in‑the‑loop workflows, and explainable models to enable oversight and scale while aiming to accelerate R&D and improve access to therapies.

2 months ago

#SHPH Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

www.stocktitan.net/news/SHPH/utah-approves-...

0 0 0 0

Shuttle Pharmaceuticals Acquires AI Health Platform Shuttle Pharmaceuticals (NASDAQ: SHPH) announced it closed the acquisition of substantially all assets and liabilities of 1542770 B.C. Ltd. d/b/a Molecule.ai for a total purchase price of $8 million payable in cash and Shuttle common stock, plus a contingent $2 million in cash and stock tied to performance milestones.An initial $3 million was paid at closing; remaining consideration will be delivered over time and, for contingent payments, subject to milestone achievement and Molecule's election of cash or equity. Shuttle said the acquisition adds an AI molecular modeling and predictive analytics platform to its drug discovery and development capabilities.

4 months ago

#SHPH Shuttle Pharmaceuticals Acquires AI Health Platform

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00 Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), today announced that it entered into a securities purchase agreement with a single investor for aggregate gross proceeds of approximately $2.5

4 months ago

#SHPH Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH) Shuttle Pharmaceuticals (NASDAQ:SHPH) announced a definitive Letter of Intent dated October 22, 2025 to acquire substantially all assets and liabilities of Molecule.ai for approximately $10 million, payable in a mix of cash and common stock with timing and ratios tied to performance milestones. Molecule.ai provides an AI platform designed to reason with scientific data, predict molecular interactions, and iterate designs in real time. Shuttle positions the deal as a strategic shift from a chemistry-focused biotech to a hybrid platform company aiming to scale discovery through perpetual machine learning.

5 months ago

#SHPH Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH) ROCKVILLE, MD / ACCESS Newswire / October 21, 2025 / Radiation therapy has always been the heavyweight of cancer treatment. It works, but it's a brute. It blasts cancer cells, hoping the good ones can withstand the damage. For decades, that was the tradeoff. Precision meant power, and power meant

5 months ago

#SHPH Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a binding term sheet to acquire substantially all assets and liabilities of 1542770 BC Ltd. ("Molecule"), a Canadian AI molecular discovery company, for a $10 million total purchase price payable in cash and Shuttle common stock.The final cash/equity mix will be determined by Shuttle and payments are subject to performance milestones. Closing requires mutual due diligence and execution of definitive agreements with customary conditions.The company said the acquisition aims to expand Shuttle's AI molecular modeling and predictive analytics capabilities to support its precision radiotherapy drug-discovery pipeline.

5 months ago

#SHPH Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Executes LOI with Molecule.ai Shuttle Pharmaceuticals (Nasdaq: SHPH) executed a non-binding letter of intent to acquire Molecule.ai, an AI drug-discovery platform founded by Dr. ZT Zhang, on October 10, 2025. The LOI contemplates Shuttle acquiring all rights to Molecule.ai and assuming its liabilities, with Molecule.ai extending its platform to support Drug-Target Interaction modeling and delivering a first version of an Agentic AI mode.Consideration is a $10 million purchase price payable at closing in a mix of cash and Shuttle common shares and subject to milestone completion; specific milestone terms are to be determined by both parties.

5 months ago

#SHPH Shuttle Executes LOI with Molecule.ai

www.stocktitan.net/news/SHPH/shuttle-execut...

0 0 0 0

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market Shuttle Pharmaceuticals (Nasdaq: SHPH) announced a non-binding letter of intent dated Oct 9, 2025 to acquire AI developer Molecule.ai for a $10 million purchase price payable at closing subject to milestones.Molecule.ai provides an AI drug-discovery platform using LLMs with modules for molecule property prediction, drug-target interaction modeling, and an initial Agentic AI mode to automate multi-step discovery workflows. Shuttle will acquire all rights and assume liabilities; Molecule.ai will extend the platform and assist hiring. Consideration will be a mix of cash and Shuttle common shares tied to milestone completion.

5 months ago

#SHPH Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

www.stocktitan.net/news/SHPH/shuttle-to-ent...

0 0 0 0

Shuttle Pharma's Glioblastoma Treatment Shows Promise as Phase 2 Trial Advances with Strong Patient Tolerance Phase 2 trial of Ropidoxuridine reports positive tolerance data with 72% completion rate. Drug targets $4B radiation therapy market with FDA Orphan status. See trial details.

7 months ago

#SHPH Shuttle Pharma Provides Second Quarter 2025 Corporate Update

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharmaceuticals Raises $4.25M to Accelerate Cancer Radiation Therapy Breakthroughs Fresh capital injection to fuel potential acquisitions and advance radiation therapy innovations. Strategic funding strengthens cancer treatment pipeline. See growth strategy.

9 months ago

#SHPH Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time Shuttle Pharmaceuticals (NASDAQ: SHPH) has announced a 1-for-25 reverse stock split effective June 16, 2025, at 12:01 a.m. ET. The company's common stock will continue trading under the symbol SHPH on the Nasdaq Capital Market with a new CUSIP number 825693401. The split will reduce outstanding shares from 26,210,037 to approximately 1,048,401 and will apply to RSU grants and warrants. Fractional shares will be rounded up to the next whole number. This strategic move aims to maintain Nasdaq listing compliance and strengthen the company's capital structure. Shuttle Pharma, a specialty pharmaceutical company, focuses on developing radiation sensitizers to improve outcomes for cancer patients undergoing radiation therapy.

9 months ago

#SHPH Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Board Approves Major 25:1 Reverse Split to Maintain Nasdaq Listing Board-approved 25:1 reverse split will reduce outstanding shares to 1.04M from 26.2M. Learn how this strategic move aims to strengthen Nasdaq compliance.

9 months ago

#SHPH Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Provides Corporate Update Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT),

10 months ago

#SHPH Shuttle Pharma Provides Corporate Update

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial Shuttle Pharmaceuticals (NASDAQ: SHPH) has reached nearly 50% enrollment in the initial randomized portion of its Phase 2 clinical trial for Ropidoxuridine, targeting glioblastoma treatment. The trial has shown promising initial results with the drug being well-tolerated and 84% of enrolled patients completing all seven cycles. The study involves 40 patients randomized into two dose levels (1,200 mg/day and 960 mg/day), with plans to add 14 more patients at the optimal dose. Ropidoxuridine, which has received FDA Orphan Drug Designation, is being developed as a radiation sensitizer for brain tumors. The trial is being conducted across six major medical centers, with final enrollment expected later this year and data readout in 2026. The company targets a significant market opportunity, with an estimated 400,000 US patients receiving radiation therapy for curative purposes annually, expected to grow by 22% over five years.

10 months ago

#SHPH Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer Shuttle Pharmaceuticals (NASDAQ: SHPH) has filed a provisional patent application with the USPTO for 'PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy.' The company is developing pretreatment diagnostic blood tests for prostate cancer through its Diagnostics subsidiary.The patent filing involves collaboration with Dr. Alan Kozikowski, whose previous research contributed to Pylarify and Pluvitco. The technology focuses on developing theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for targeted therapy delivery.According to market data, the Global PSMA PET Imaging Market reached $1.5 billion in 2022 and is projected to reach $2.0 billion by 2030. Pluvitco, a targeted radiopharmaceutical treatment, has a predicted market size of $2 billion.

11 months ago

#SHPH Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering Shuttle Pharmaceuticals Holdings (Nasdaq: SHPH) has announced the pricing of a $5.75 million underwritten public offering, consisting of 19,166,667 shares of common stock at $0.30 per share. The offering, expected to close on March 13, 2025, is being conducted on a firm commitment basis with WestPark Capital as the Sole Book-Runner.The net proceeds will fund three key initiatives:Phase II clinical trial for lead product candidateMarketing and advertising servicesWorking capital and general corporate purposesShuttle Pharma, founded in 2012 by Georgetown University Medical Center faculty, focuses on improving outcomes for cancer patients treated with radiation therapy by developing radiation sensitizers to enhance treatment effectiveness while limiting side effects.

1 year ago

#SHPH Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Shuttle Pharma Provides Corporate Update and Reports 2024 Results GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a...

1 year ago

#SHPH Shuttle Pharma corporate update & Annual Report
www.globenewswire.com/news-release...

0 0 0 0

Shuttle Pharma Provides Corporate Update and Reports 2024 Results Shuttle Pharmaceuticals (NASDAQ: SHPH) has provided a corporate update for 2024, highlighting significant progress in its cancer treatment programs. The company reported 40% enrollment completion in the Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment, with 16 out of 40 initial patients enrolled and 8 patients completing all seven cycles.The trial is being conducted at several prestigious cancer centers including Georgetown University Medical Center and UNC Medical Center. Additionally, Shuttle Pharma's Diagnostics subsidiary entered a research agreement with UCSF to develop a PSMA ligand for cancer diagnosis and therapy.The company secured additional funding, including a $237,500 investment from CEO Dr. Anatoly Dritschilo. The company's focus remains on developing radiation sensitizers to enhance cancer treatment outcomes and advancing diagnostic tools for predicting radiation therapy success, particularly in prostate cancer treatment.

1 year ago

#SHPH Shuttle Pharma Provides Corporate Update and Reports 2024 Results

www.stocktitan.net/news/SHPH/shuttle-pharma...

1 0 0 0

Giants67

@giants1967.bsky.social

1 year ago

#SAKL Eliminates $7.869M Debt
#UCLE Forecasts a 50% Increase Revenue
#MSCH Accelerates Acquisition
#SHPH Milestone in Patient Enrollment
#BTC.C Investment into ChessGold
#RELT Product offering - Cortex AI
#ASII Achieves $39.5M Revenue
#IQST Shares Future Vision
#RITE Finalizing Merger Agreements

0 0 0 0

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...

1 year ago

#SHPH Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
www.globenewswire.com/news-release...

0 0 0 0

Shuttle Pharma Hits 25% Enrollment in Phase 2 Glioblastoma Trial for Promising Radiation Drug Shuttle Pharmaceuticals reaches key milestone in Phase 2 trial of Ropidoxuridine, targeting aggressive brain cancer with FDA-designated orphan drug at major cancer centers.

1 year ago

#SHPH Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #SHPH ) Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

#StockMarket #News

0 0 0 0

Shuttle Pharmaceuticals Partners with UCSF for Breakthrough Prostate Cancer Diagnostic Development SHPH collaborates with UCSF to advance novel PSMA-B ligand technology, targeting the $2B prostate cancer imaging market. Key research focuses on diagnostic potential.

1 year ago

#SHPH Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

www.stocktitan.net/news/SHPH/shuttle-pharma...

0 0 0 0

Giants67

@giants1967.bsky.social

1 year ago

ADVANCED CANCER TREATMENT | Greenplanetmicrocaps

#SHPH #AZN #MRK Strong Data from NIH Sponsored Clinical Trial Suggests Ropidoxuridine Could be Major Advancement for Cancer Patients and Big Win for Shuttle Pharmaceuticals’ Shareholders
richardacavalli.wixsite.com/greenplanetm...

0 0 0 0

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and...

1 year ago

#SHPH Shuttle Pharmaceuticals has its first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial
www.globenewswire.com/news-release...

0 0 0 0

Giants67

@giants1967.bsky.social

1 year ago

CANCER MOONSHOT? | Greenplanetmicrocaps

#SHPH #NWBO FINALLY REALLY PROMISING CANCER TREATMENTS
Northwest Bio and Shuttle Pharmaceuticals Combo Could be the Giant Leap to New Standard of Care for Glioblastoma and Solid Tumor Cancers
richardacavalli.wixsite.com/greenplanetm...

0 0 0 0